Qualigen Therapeutics, Inc.
QLGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,522 | $139,456 | $247,375 | $1,569,415 |
| - Cash | $1,175 | $402 | $3,166 | $17,538 |
| + Debt | $0 | $1,299 | $1,757 | $1,677 |
| Enterprise Value | $348 | $140,354 | $245,966 | $1,553,553 |
| Revenue | $0 | $5,205 | $4,984 | $5,654 |
| % Growth | -100% | 4.4% | -11.9% | – |
| Gross Profit | $0 | -$4 | $681 | $1,321 |
| % Margin | – | -0.1% | 13.7% | 23.4% |
| EBITDA | -$5,244 | -$11,300 | -$13,841 | -$22,341 |
| % Margin | – | -217.1% | -277.7% | -395.2% |
| Net Income | -$6,159 | -$13,417 | -$21,035 | -$17,897 |
| % Margin | – | -257.8% | -422.1% | -316.6% |
| EPS Diluted | -17.28 | -2.46 | -5.48 | -6.1 |
| % Growth | -602.4% | 55.1% | 10.2% | – |
| Operating Cash Flow | -$6,328 | -$10,304 | -$13,248 | -$14,731 |
| Capital Expenditures | $0 | $0 | -$319 | -$141 |
| Free Cash Flow | -$6,328 | -$10,304 | -$13,567 | -$14,872 |